Boehringer Ingelheim is a leading pharmaceutical company with a rich history that dates back to 1885 when it was founded in Ingelheim, Germany. The company has made significant contributions to global healthcare over the years through the development of innovative medicines and cutting-edge research.

Boehringer Ingelheim is a family-owned company that believes in long-term investments in science, research and technology to make a positive impact on the world. The company’s mission is to improve the health and wellbeing of people and animals by developing innovative medicines.

Over the past century, Boehringer Ingelheim has grown to become one of the world’s largest pharmaceutical companies with a presence in over 50 countries. Today, the company employs over 50,000 people worldwide and invests more than 20% of its net sales in research and development.

One of the key areas of focus for Boehringer Ingelheim is respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The company has developed a range of treatments for these conditions, including Spiriva, which is the most widely prescribed COPD medication in the world. The drug helps to improve lung function and reduce respiratory symptoms in patients with COPD.

In addition to respiratory diseases, Boehringer Ingelheim is also committed to developing treatments for other major diseases such as cancer, diabetes, and cardiovascular diseases. The company’s research focuses on developing therapies that target the underlying causes of these conditions. For example, the company’s cancer research program focuses on the development of drugs that inhibit the growth of cancer cells while sparing healthy cells.

Boehringer Ingelheim has also made significant contributions to the field of animal health. The company offers a wide range of products and services for the prevention and treatment of diseases in animals. This includes medicines for livestock, pets, and horses. The company’s animal health portfolio includes vaccines, antibiotics, and antiparasitics.

Boehringer Ingelheim is also committed to sustainable business practices. The company believes that sustainability is essential to its long-term success and has implemented a range of initiatives to reduce its environmental footprint. For example, the company has implemented a range of energy-saving measures at its manufacturing sites and has reduced its greenhouse gas emissions by more than 20% since 2000.

In addition to its sustainability efforts, Boehringer Ingelheim is also committed to giving back to the community. The company supports a range of charitable organizations and initiatives around the world. For example, the company’s Making More Health program aims to improve healthcare access in developing countries.

In conclusion, Boehringer Ingelheim is a leading pharmaceutical company that has made significant contributions to global healthcare over the past century. The company’s commitment to long-term investments in science, research, and technology has made it a leader in the development of innovative medicines for major diseases. With a focus on sustainability and giving back to the community, Boehringer Ingelheim is a company that truly embodies the values of responsible corporate citizenship.

Quest'articolo è stato scritto a titolo esclusivamente informativo e di divulgazione. Per esso non è possibile garantire che sia esente da errori o inesattezze, per cui l’amministratore di questo Sito non assume alcuna responsabilità come indicato nelle note legali pubblicate in Termini e Condizioni
Quanto è stato utile questo articolo?
0Vota per primo questo articolo!